secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001140361-26-006176
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.02, 3.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics raises $25M via Series B convertible preferred; pro forma cash $70M
--------------------------------------------------------------------------------

- Closed private placement of 7,374,632 shares of Series B Non-Voting Convertible Preferred at $3.39/share for $25M.
- Proceeds to advance gene therapy clinical programs, working capital, and general corporate purposes.
- Preliminary cash balance $45M as of Dec 31, 2025; pro forma $70M after private placement proceeds.
- Conversion to common stock requires stockholder approval at 2026 annual meeting; filing of Certificate of Designation.
- Company entered into Registration Rights Agreement to register resale of conversion shares by April 19, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036126006176/0001140361-26-006176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036126006176/ef20066083_form8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-006176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer